+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

China Independent Clinical Laboratory Industry Report, 2019-2025

  • ID: 4769738
  • Report
  • April 2019
  • Region: China
  • 140 Pages
  • Research In China

Enquire about COVID-19 updates for this product.

Enquire Now
China's Independent Clinical Laboratory Market Showed a CAGR of 40.9% During 2010-2018 and Approximated Rmb18.6 Billion in 2018, a Year-On-Year Increase of 37.8%. By 2025, it is Expected to Reach Rmb96.7 Billion with the Growth Rate Of Above 20%

FEATURED COMPANIES

  • Amoy Diagnostics
  • CapitalBio Corporation
  • DAAN Gene
  • Deyi Diagnostics
  • DIAN Diagnostics
  • Kindstar Global
  • MORE

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below the 40% or more seen in Europe, the United States, and Japan. The main reason for this is that the laboratory and pathology departments of public hospitals occupy the leading position in the industry in China.

In China, large independent clinical laboratories can provide more than 2,000 test items, while first-class AAA hospitals can only offer over 300-500 test items. With the acceleration of population aging, the higher incidence of various chronic diseases and favorable policies, the penetration rate and scale of China's independent clinical laboratory industry will increase year by year.

China's independent clinical laboratory market size enjoyed a CAGR of 40.9% during 2010-2018 and stood at RMB18.6 billion in 2018, a year-on-year increase of 37.8%. By 2025, it is expected to reach RMB96.7 billion with the growth rate of above 20%.

As of September 2018, there had been 1,271 independent clinical laboratories in China, indicating gradually intensified competition in the industry. At present, major players in China include KingMed Diagnostics, ADICON, DIAN Diagnostics, DAAN Gene, MedicalSystem Biotechnology and others. KingMed Diagnostics is the industry’s leader with a 22.8% market share in 2018.

As the competition intensifies, the market share of KingMed Diagnostics has reduced from 32.9% in 2014 to 22.8% in 2018. In the future, small ICL companies without competitive advantages are likely to be phased out and the industry will become more concentrated.

China Independent Clinical Laboratory Industry Report, 2019-2025 highlights the following:

  • Overview of China’s independent clinical laboratory industry, covering development environment, status quo, market size, competitive landscape, and development trend
  • Upstream and downstream sectors of China’s independent clinical laboratory industry
  • Operation, gross margin, R&D investment, independent clinical laboratory business and development strategy of 21 companies in China

The Chinese Version of this Report is Available on Request.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amoy Diagnostics
  • CapitalBio Corporation
  • DAAN Gene
  • Deyi Diagnostics
  • DIAN Diagnostics
  • Kindstar Global
  • MORE

1. Overview of Independent Clinical Laboratory
1.1 Definition
1.2 Industry Chain

2. Overview of China Independent Clinical Laboratory Industry
2.1 Policy Environment
2.1.1 Access Policy
2.1.2 Industry Policy
2.2 International Environment
2.2.1 Status Quo
2.2.2 Benchmarking Enterprises
2.3 Status Quo
2.4 Market size
2.5 Competitive Landscape
2.6 Development Trends
2.6.1 Industry Scale Expands Constantly
2.6.2 Hierarchical Medical System Will Boost the Rapid Development of the Industry
2.6.3 The Laboratory Outsourcing Proportion of Public Hospitals Will Rise due to Cost Control
2.6.4 High-end Test Items Will Make More Revenue Contribution
2.6.5 The Rapid Development of Private Hospitals Will Stimulate the Demand in the Independent Clinical Laboratory Market
2.6.6 Independent Clinical Laboratory Institutions Will Become Technical Leaders amid Quick Technological Upgrades
2.6.7 The Aging Population Balloons and the Demand for Medical Laboratory Will Soar
2.6.8 Internet Will Stimulate the Business Model Upgrade of Independent Clinical Laboratory Industry
2.6.9 Intensified industry competition Forced Small Capacity to Withdraw

3. Upstream and Downstream Sectors of China Independent Clinical Laboratory Industry
3.1 Upstream Sector
3.1.1 Status Quo
3.1.2 Market Size
3.1.3 Competitive Landscape
3.1.4 Development Trend
3.2 Downstream Sector
3.2.1 Quantity
3.2.2 Medical Services
3.2.3 Revenue
3.2.4 Health Costs

4. Key Players
4.1 KingMed Diagnostics
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D and Investment
4.1.6 Major Customers
4.1.7 Independent Clinical Laboratory Business
4.1.8 Development Strategy
4.2 DIAN Diagnostics
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D and Investment
4.2.6 Independent Clinical Laboratory Business
4.2.7 Development Strategy
4.3 Shanghai Labway Clinical Laboratory
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D and Investment
4.3.6 Independent Clinical Laboratory Business
4.4 DAAN Gene
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 R&D and Investment
4.4.5 Major Customers
4.4.6 Independent Clinical Laboratory Business
4.4.7 Development Strategy
4.5 ADICON Clinical Laboratories
4.5.1 Profile
4.5.2 Independent Clinical Laboratory Business
4.5.3 Developments
4.6 NYMPHAVN Biotechnology
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D and Investment
4.6.6 Independent Clinical Laboratory Business
4.6.7 Development Strategy
4.7 SurExam Biotechnology
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 Independent Clinical Laboratory Business
4.8 MedicalSystem Biotechnology 
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 R&D and Investment
4.8.6 Independent Clinical Laboratory Business
4.8.7 Development Strategy
4.9 Beijing Lawke Health Laboratory
4.9.1 Profile
4.9.2 Operation
4.9.3 Revenue Structure
4.9.4 Gross Margin
4.9.5 R&D and Investment
4.10 Beijing Lepu Gene Technology
4.10.1 Profile
4.10.2 Operation
4.10.3 Revenue Structure
4.10.4 Gross Margin
4.10.5 R&D and Investment
4.10.6 Major Customers
4.11 Shanghai Biotecan Pharmaceuticals
4.11.1 Profile
4.11.2 Operation
4.11.3 Revenue Structure
4.11.4 Gross Margin
4.11.5 Independent Clinical Laboratory Business
4.12 Jiangsu Superbio Life Science
4.12.1 Profile
4.12.2 Operation
4.12.3 Revenue Structure
4.12.4 Gross Margin 
4.12.5 Financing
4.13 Amoy Diagnostics
4.13.1 Profile
4.13.2 Operation
4.13.3 Revenue Structure
4.13.4 Gross Margin
4.13.5 Independent Clinical Laboratory Business
4.13.6 Development Strategy
4.14 Guangdong Hybribio Biotech 
4.14.1 Profile
4.14.2 Operation
4.14.3 Revenue Structure
4.14.4 Gross Margin
4.14.5 R&D
4.14.6 Independent Clinical Laboratory Business
4.14.7 Development Strategy
4.15 Other Enterprises
4.15.1 Kindstar Global
4.15.2 CapitalBio Corporation
4.15.3 Beijing Adinovo Gene Technology Co., Ltd.
4.15.4 Deyi Diagnostics
4.15.5 IPE Center for Clinical Laboratory
4.15.6 Centre Testing International Group Co., Ltd. (CTI)
4.15.7 SinoPath Diagnosis

Note: Product cover images may vary from those shown
  • ADICON Clinical Laboratories
  • Amoy Diagnostics
  • Beijing Adinovo Gene Technology Co., Ltd.
  • Beijing Lawke Health Laboratory
  • Beijing Lepu Gene Technology
  • CapitalBio Corporation
  • Centre Testing International Group Co., Ltd. (CTI)
  • DAAN Gene
  • Deyi Diagnostics
  • DIAN Diagnostics
  • Guangdong Hybribio Biotech
  • IPE Center for Clinical Laboratory
  • Jiangsu Superbio Life Science
  • Kindstar Global
  • KingMed Diagnostics
  • MedicalSystem Biotechnology
  • NYMPHAVN Biotechnology
  • Shanghai Biotecan Pharmaceuticals
  • Shanghai Labway Clinical Laboratory
  • SinoPath Diagnosis
  • SurExam Biotechnology
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll